Foreign Affairs
Process starts for authorisation of Russian Sputnik V vaccine

The European Medicines Agency is in the early stages of the process to grant authorisation for the Russian Sputnik V vaccine against Covid-19.

Experts in this health sector will be analysing aspects of the safety, quality and effectiveness of the vaccine.

Sputnik V is the seventh vaccine to be examined through this very important procedure, following BionTech/Pfizer, Moderna, AstraZeneca, Johnson & Johnson, Novavax and Curevac.

Despite this, expert Dr Peter Liese, who is also a member of the EPP, stated that major doubts still exist about whether Sputnik V can be as effective as other vaccines already on the market.